Source: Mass Device (
click here to go to the source)
by MassDevice staff
BSD Medical initiates a Phase I/II clinical study of its hyperthermia system for the treatment of patients with recurrent rectal cancer.
BSD Medical logo
BSD Medical Corp. (NSDQ:BSDM) initiated its Phase I/II HyRec-Trial, evaluating its BSD-2000 Hyperthermia System to treat patients with locally recurrent rectal cancer.
The clinical trial, which has been approved by the German Cancer Society, will enroll 59 patients to evaluate the feasibility and the efficacy of adding hyperthermia to a multimodal treatment regimen, the company said.
